戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 .3 +/- 3.3 to 13.1 +/- 3.7 (p < 0.001) after chelation therapy.
2 CN2/SLC22A17 system and is inhibited by iron chelation therapy.
3  chelator currently in clinical use for iron chelation therapy.
4 ave been used to monitor patient response to chelation therapy.
5   Eight patients had siderosis and underwent chelation therapy.
6 to 2012 after universal availability of iron chelation therapy.
7 t side effects associated with systemic EDTA chelation therapy.
8 last decade has ushered in a new era in iron chelation therapy.
9 = 45 microg/dL, the threshold for initiating chelation therapy.
10 a (IL-1beta), and interleukin-6 (IL-6) after chelation therapy.
11 information to liver and cardiac iron during chelation therapy.
12 d potential therapeutic agents for metal-ion chelation therapy.
13 of MDS to fully evaluate the benefit of iron chelation therapy.
14 matory mediators and glutathione (GSH) after chelation therapy.
15 sted of RBC transfusions and, for some, iron chelation therapy.
16 y recent discoveries and novel approaches to chelation therapy.
17 d and should not be used to direct long-term chelation therapy.
18  raising the possibility of considering iron chelation therapy.
19 g 330 patients who had received deferoxamine chelation therapy, 224 (68%) reported no complications.
20 y reduced cardiac iron more effectively than chelation therapy alone.
21 the disease, which might impair an effective chelation therapy and lead to severe consequences due to
22 lt and pediatric patients need to begin iron chelation therapy and to monitor their progress.
23 ly positive results of TACT (Trial to Assess Chelation Therapy), and a body of epidemiological data s
24  of MDS may not be the major benefit of iron chelation therapy, and present evidence suggesting a pot
25                        Current protocols for chelation therapy appear ineffective in preventing such
26 nse of non-transferrin-bound iron (NTBPI) to chelation therapy are largely unknown and have important
27 organ dysfunction, and complications of iron chelation therapy are strongly age-dependent in North Am
28 ent primarily relies on transfusion and iron-chelation therapy, as well as splenectomy in specific ca
29                                         Iron chelation therapy can be effective in these MDS cases, b
30 may exist in the aging lens, suggesting that chelation therapy could be beneficial in delaying catara
31 aken together, these results suggest that Cu-chelation therapy could be repurposed to treat cancers c
32 obile state, confirming the relevance of the chelation therapy currently used to treat Mn intoxicatio
33                          The trial to assess chelation therapy demonstrated a significant (P=0.035) 1
34 with a history of myocardial infarction,EDTA chelation therapy did not have a detectable effect on QO
35                           Adjustment of iron chelation therapy did not improve visual function.
36 actorial design with edetate disodium (EDTA) chelation therapy, did not reduce cardiovascular events
37                                      Despite chelation therapy, diffuse iron deposition was occurring
38 ients showing a positive response after iron chelation therapy displayed higher levels of PI-PLCbeta1
39 ient evidence to indicate the routine use of chelation therapy for all post-myocardial infarction pat
40 e within normal limits, suggesting that iron-chelation therapy for FRDA may be problematic.
41        To evaluate the possible role of iron-chelation therapy for FRDA, we measured serum iron and f
42 ildren < 5 years of age in need of emergency chelation therapy for lead poisoning.
43 not sufficient to support the routine use of chelation therapy for treatment of patients who have had
44  (n = 780) of dimercaptosuccinic acid (DMSA) chelation therapy found reduced blood lead levels in chi
45              Recent developments in gene and chelation therapy give hope of better prognosis for pati
46                                         EDTA chelation therapy has been in off-label use for the trea
47                                         This chelation therapy has the potential to mitigate cobalt t
48                                       During chelation therapy, high levels of gadolinium in excreted
49           Although clinical benefits of iron chelation therapy (ICT) in red blood cell (RBC) transfus
50 with TDT over the age of 18 who were on iron-chelation therapy (ICT) were consecutively investigated.
51                           Mitochondrial iron chelation therapy improved colitis and demonstrated an e
52  if mimicked by designer drugs, could impact chelation therapies in iron-overload diseases.
53                    After institution of iron chelation therapy in 2010, no child with thalassemia maj
54                               The success of chelation therapy in controlling iron overload in patien
55                             The role of iron chelation therapy in myelodysplastic syndrome (MDS) rema
56             We also describe our approach to chelation therapy in the patient with iron overload.
57                  No data support the role of chelation therapy in this population.
58 e trials to examine the potential benefit of chelation therapy in this setting.
59 es an update on advances in the area of iron chelation therapy, including new indications and uses of
60 etrospective analysis demonstrates that iron chelation therapy is associated with prolonged survival
61 ve as any lead chelator currently available, chelation therapy is not indicated for children with the
62                                              Chelation therapy is used to 'de-copper' patients but ne
63 l capillary network for blood supply, copper chelation therapy may hold promise as an anti-cancer str
64  issues in clinical trials, herbal medicine, chelation therapy, mind/body (meditation) therapy, and a
65 overload correlated with lower compliance to chelation therapy (P<0.013).
66 measures included environmental remediation, chelation therapy, public health education, and control
67            Charges for patients who required chelation therapy ranged from $31 143 to $50 852 per pat
68  cardiac siderosis, amlodipine combined with chelation therapy reduced cardiac iron more effectively
69                                              Chelation therapy reduces physiological stores of vascul
70 I-PLCbeta1 quantification could predict iron chelation therapy response in MDS.
71 eposits was associated with lower anti-tumor chelation therapy response.
72 ches to blood transfusions, splenectomy, and chelation therapy shifted during this period.
73                                Targeted EDTA chelation therapy successfully reversed calcification in
74  Institutes of Health.funded Trial to Assess Chelation Therapy (TACT) randomized 1708 stablecoronary
75                 In 2013, the Trial to Assess Chelation Therapy (TACT) reported that edetate disodium
76                 In 2013, the Trial to Assess Chelation Therapy (TACT) reported that in 1708 patients
77                          The Trial to Assess Chelation Therapy (TACT) showed clinical benefit of an E
78  suggest a molecular basis for exploiting Cu-chelation therapy to prevent autophagy signalling to lim
79 we tested a targeted nanoparticle-based EDTA chelation therapy to reverse CKD-associated MAC.
80 e to chronic anemia, iron overload, and iron chelation therapy toxicity in few previous studies.
81                          The trial to assess chelation therapy was a $30 million National Institutes
82 ne thalassemic patients without a history of chelation therapy were included as a control group.
83 derate strength recommendation to begin iron chelation therapy when indicated.
84 blind, placebo-controlled trial of oral iron chelation therapy with deferasirox in this population.
85                                              Chelation therapy with disodium EDTA has been used for m
86                       Participants underwent chelation therapy with intravenous CaNa(2)EDTA for 2 day
87 nt haemoglobinopathies require lifelong iron chelation therapy with one of the three iron chelators (